Genetically modified bacteria

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

Retrieved on: 
Saturday, April 6, 2024
IOP, Glaucoma, Conditional sentence, Ocular hypertension, Endothelium, Arm, Medicine, Safety, Risk, ASCRS, Patient, Protocol, MD, Genetically modified bacteria, Science, Intraocular pressure, Travoprost, FDA

BEDFORD, Mass., April 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced positive Phase 2 data for PAXTRAVA (travoprost intracameral implant or OTX-TIC) in patients with open-angle glaucoma or ocular hypertension (reported together as “glaucoma”, below) The data are being presented by Mark Gallardo, MD during the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting.

Key Points: 
  • “Ocular is very pleased to report positive six-month topline results for PAXTRAVA in the Phase 2 glaucoma study.
  • We designed the Phase 2 clinical trial to evaluate PAXTRAVA over several time points that we believe are clinically meaningful, through six months.
  • Most ocular AEs within 3 days were deemed related to the injection procedure by the investigators.
  • I am enthusiastic about PAXTRAVA because of the positive, durable IOP reductions, accompanied by a good overall safety profile,” said Mark Gallardo, MD.

Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
Tuesday, April 2, 2024
Webcast, SAN, Genetically modified bacteria, Conference

SAN CARLOS, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9 at 12:45 p.m.

Key Points: 
  • SAN CARLOS, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9 at 12:45 p.m.
  • ET / 9:45 a.m. PT.
  • A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com .
  • A replay of the webcast will be available for approximately 30 days following the conference.

QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirements

Retrieved on: 
Monday, March 18, 2024
BCG, IGRA, Disease, Infection, Tuberculosis, World Tuberculosis Day, Incidence, Partnership, Molecular diagnostics, Interferon gamma release assay, CPD, Patient, Ageing, Epidemiology, Genetically modified bacteria, Senior, TST, IPPA, MPH, CDC, Vaccination, QIAGEN, Gold, WHO, TB, Physician, QGEN

Germantown, Maryland, and Venlo, the Netherlands, March 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements.

Key Points: 
  • Germantown, Maryland, and Venlo, the Netherlands, March 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements.
  • A special focus will be on the new Interferon Gamma Release Assay (IGRA) requirements and the associated benefits for patients and healthcare providers.
  • This collaboration follows the U.S. Centers for Disease Control and Prevention (CDC) updating its guidelines for new TB screening requirements for immigrants to the United States.
  • Alexandra Ortega, MPH, MCHES, Executive Director of the IPPA, said, “Working together with QIAGEN allows us to educate panel physicians on the latest TB screening requirements, ensuring patients receive the most accurate and efficient testing available.

$3.8 Billion MRSA Drugs Markets by Drug Class, Disease Indication, Route of Administration, Distribution Channel, and Region - Global Forecast to 2032 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 29, 2024
Health, Pharmaceutical, MRSA, Urbanization, Growth, Prevalence, Fungal infection, Pharmacy, Research, Bacteria, Genetically modified bacteria, Tetracycline, Infection, Skin, Lipopeptide, Market, Administration, CA-MRSA, Pharmaceutical industry

The "MRSA Drugs Market by MRSA Type, Drug Class, Disease Indication, Route of Administration, Distribution Channel, and Region 2024-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "MRSA Drugs Market by MRSA Type, Drug Class, Disease Indication, Route of Administration, Distribution Channel, and Region 2024-2032" report has been added to ResearchAndMarkets.com's offering.
  • Moreover, the augmenting awareness regarding different forms of bacterial infection is leading to a higher uptake of MRSA drugs.
  • The report has provided a detailed breakup and analysis of the MRSA drugs market based on the MRSA type.
  • The report has provided a detailed breakup and analysis of the MRSA drugs market based on the route of administration.

PRECISIO BIOTIX THERAPEUTICS ANNOUNCES COLLABORATION WITH MAYO CLINIC

Retrieved on: 
Thursday, March 14, 2024
Enzyme, Health, Lysin, Education, Patient, Lung, Mayo Clinic, Research, Bacteria, AI, AMR, Infection, Genetically modified bacteria, Therapy, Engineering, Pharmaceutical industry

DOVER, Del., March 14, 2024 /PRNewswire/ -- Precisio Biotix Therapeutics ("Precisio") today announced it has entered into an agreement with Mayo Clinic. The collaboration will include co-development of novel precision antibacterials targeting indications prone to antimicrobial-resistant (AMR) infections.

Key Points: 
  • The announcement by Mark Engel, Precisio Biotix's Chairman and CEO, highlights another step by Precisio Biotix to advance novel precision biological antibacterials.
  • DOVER, Del., March 14, 2024 /PRNewswire/ -- Precisio Biotix Therapeutics ("Precisio") today announced it has entered into an agreement with Mayo Clinic.
  • Dr. Assaf Raz, VP of R&D, stated: "We are delighted to work with Mayo Clinic.
  • Mayo Clinic has a financial interest in the technology and will use any revenue it receives to support its patient care, education and research.

Biocomposites announces approval of STIMULAN in Brazil as an antibiotic carrier for treating bacterial infection

Retrieved on: 
Wednesday, March 13, 2024
USP, Infection, Debridement, Hip, Genetically modified bacteria, Surgeon, Wound healing, Orthopedic surgery, Traumatology

KEELE, England, March 13, 2024 /PRNewswire/ -- Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, is pleased to announce the approval in Brazil of STIMULAN as a calcium matrix antibiotic carrier for use in wound healing and the treatment of bacterial infection.

Key Points: 
  • Brazil joins a growing list of more than 60 countries around the world where STIMULAN is the only calcium matrix approved to carry antibiotics in bone and soft tissue.
  • This approval gives surgeons in Brazil, a country of 217 million people, the flexibility to select and source their preferred choice of antibiotic to suit each patient-specific treatment plan.
  • STIMULAN enables high concentrations of antibiotic to be applied at the point of infection, leading to reduced rates of reinfection, decreased hospital readmissions, and significantly improved patient outcomes.
  • We use STIMULAN concomitantly with the antibiotic vancomycin to completely fill the bone lesion, following debridement, and close with full soft tissue coverage."

Biocomposites announces approval of STIMULAN in Brazil as an antibiotic carrier for treating bacterial infection

Retrieved on: 
Wednesday, March 13, 2024
USP, Infection, Debridement, Hip, Genetically modified bacteria, Surgeon, Wound healing, Orthopedic surgery, Traumatology

KEELE, England, March 13, 2024 /PRNewswire/ -- Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, is pleased to announce the approval in Brazil of STIMULAN as a calcium matrix antibiotic carrier for use in wound healing and the treatment of bacterial infection.

Key Points: 
  • Brazil joins a growing list of more than 60 countries around the world where STIMULAN is the only calcium matrix approved to carry antibiotics in bone and soft tissue.
  • This approval gives surgeons in Brazil, a country of 217 million people, the flexibility to select and source their preferred choice of antibiotic to suit each patient-specific treatment plan.
  • STIMULAN enables high concentrations of antibiotic to be applied at the point of infection, leading to reduced rates of reinfection, decreased hospital readmissions, and significantly improved patient outcomes.
  • We use STIMULAN concomitantly with the antibiotic vancomycin to completely fill the bone lesion, following debridement, and close with full soft tissue coverage."

Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain

Retrieved on: 
Thursday, March 7, 2024
Modic, Safety, Disability, Pharmacokinetics, Patient, Pain, Medication, Psychotherapy, Low back pain, Genetically modified bacteria, Pharmaceutical industry

Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain

Key Points: 
  • Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain
    London, UK, 07 March 2024 – Persica Pharmaceuticals Ltd, a privately held, clinical stage pharmaceutical company developing an antibiotic formulation for intradiscal injection to treat Chronic Low Back Pain (CLBP) and disability associated with bone oedema (Modic 1), which is caused by bacterial infection, today announces the completion of enrolment of participants into its Phase 1b Modic Trial.
  • CLBP is a leading cause of disability with significant unmet medical need and contributes to the overuse of chronic opioid therapy.
  • The Modic Trial is a placebo-controlled randomised clinical trial assessing the safety and efficacy of PP353 as a treatment for patients with CLBP associated with Modic 1 changes.
  • Dr Steve Ruston, Chief Executive Officer of Persica Pharmaceuticals Ltd, said: “CLBP is a debilitating condition which affects millions of people.

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

Retrieved on: 
Monday, March 4, 2024
SAN, Immunization, PCV, Serology, Life, Vaccine, Safety, Meningitis, Genetically modified bacteria, IPD, Tolerability, Infant, Disease, Streptococcus pneumoniae, Fungal infection

SAN CARLOS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the completion of enrollment in its Phase 2 study evaluating VAX-24, a broad-spectrum, carrier-sparing 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in healthy infants. Vaxcyte expects to announce topline safety, tolerability and immunogenicity data from the Phase 2 study primary three-dose immunization series by the end of the first quarter of 2025, followed by topline data from the booster dose by the end of 2025.

Key Points: 
  • Vaxcyte expects to announce topline safety, tolerability and immunogenicity data from the Phase 2 study primary three-dose immunization series by the end of the first quarter of 2025, followed by topline data from the booster dose by the end of 2025.
  • “Completing enrollment of the VAX-24 study with more than 800 healthy infants demonstrates yet another significant milestone in the development of our VAX-24 and VAX-31 PCV candidates,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte.
  • “We believe VAX-24 has a potential best-in-class profile for this vital population and is designed to cover more serotypes than any infant pneumococcal vaccine on-market or in U.S. clinics today.
  • “Given the significant burden of disease in young children, there remains a need for broader-spectrum vaccines like VAX-24 and VAX-31, our next-generation 31-valent PCV candidate, that are designed to provide greater protection than the current standard-of-care.”

Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, February 27, 2024
Licensure, Investment, Growth, Exercise, Tolerability, Immunization, Host, Trial of the century, Ageing, PCV20, PCV, P-value, Safety, BLA, Success, Phase 10, Genetically modified bacteria, Net, G&A, CMC, SAN, Research and development, ID, OPA, Conference, The Lancet, Biologics license application, Breakthrough therapy, Advisory Committee, PCV15, POC, FDA, End, Food, Breakthrough, Element, Fireside chats, Administration, IPD

-- Significant Progress in Establishing Global Commercial Manufacturing Capacity for Vaxcyte's PCV Candidates, Including Expanded Collaboration with Lonza --

Key Points: 
  • ET / 1:30 p.m. PT --
    SAN CARLOS, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
  • Additionally, as part of ongoing Chemistry, Manufacturing and Controls (CMC)-focused discussions, Vaxcyte received encouraging input from the FDA regarding the VAX-24 adult licensure requirements.
  • The six-month safety data from both studies showed safety and tolerability results for VAX-24 similar to PCV20 at all doses studied.
  • Vaxcyte will host a conference call and webcast to discuss this announcement today, February 27, 2024, at 4:30 p.m.